{"protocolSection":{"identificationModule":{"nctId":"NCT01109524","orgStudyIdInfo":{"id":"CA225-346"},"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer","officialTitle":"Cisplatin and Vinorelbine in Combination With Cetuximab as First Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): a Single Arm Multicenter Safety Phase 2 Study"},"statusModule":{"statusVerifiedDate":"2015-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-07"},"primaryCompletionDateStruct":{"date":"2012-09","type":"ACTUAL"},"completionDateStruct":{"date":"2012-09","type":"ACTUAL"},"studyFirstSubmitDate":"2010-04-22","studyFirstSubmitQcDate":"2010-04-22","studyFirstPostDateStruct":{"date":"2010-04-23","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-09-12","resultsFirstSubmitQcDate":"2013-11-15","resultsFirstPostDateStruct":{"date":"2013-12-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-11-24","lastUpdatePostDateStruct":{"date":"2015-12-24","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine."},"conditionsModule":{"conditions":["Lung Neoplasms","Carcinoma","Cancer of the Lung","Non-Small-Cell Lung Carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":72,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cetuximab + Cisplatin + Vinorelbine","type":"EXPERIMENTAL","interventionNames":["Drug: Cetuximab","Drug: Cisplatin","Drug: Vinorelbine"]}],"interventions":[{"type":"DRUG","name":"Cetuximab","description":"Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision","armGroupLabels":["Cetuximab + Cisplatin + Vinorelbine"],"otherNames":["Erbitux","BMS-564717"]},{"type":"DRUG","name":"Cisplatin","description":"Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles","armGroupLabels":["Cetuximab + Cisplatin + Vinorelbine"],"otherNames":["Platinol"]},{"type":"DRUG","name":"Vinorelbine","description":"Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles","armGroupLabels":["Cetuximab + Cisplatin + Vinorelbine"],"otherNames":["Navelbine"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Any Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population","description":"AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=medical event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. MedDRA version 14.0. Severity of AEs were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.","timeFrame":"Day 1 up to 30 days after last dose"},{"measure":"Number of Participants With Grades 3 and 4 Treatment-emergent Adverse Events (AEs) of Special Interest - Treated Population","description":"Special interest AEs: acneform rash, infusion reaction, cardiac adverse event, febrile neutropenia, infection (includes all terms except sepsis), sepsis, interstitial lung disease, renal failure, and thromboembolic events. Except for interstitial lung disease, these were composite terms combining several preferred/other level MedDRA terms (MedDRA version 14.0). Except for Grade (GR)3 and 4 infusion reactions, AE severity were graded per the NCI-CTC, version 3.0: Gr 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Severity of Gr 3 - 4 infusion reactions were: Gr 3=symptomatic bronchospasm, requiring parenteral medication(s), with or without urticaria; allergy-related edema/angioedema; Gr 4=a life-threatening event characterized by the same symptomatology as a Gr 3, complicated by symptomatic hypotension or oxygen saturation 70% or less. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.","timeFrame":"Day 1 to 30 days after last dose"},{"measure":"Number of Participants With Liver Function Serum Chemistry Laboratory Abnormalities - Treated Population","description":"ULN=Upper limit of normal among all laboratory ranges. ALT=alanine transaminase; AST=aspartate aminotransferase; ALP=alkaline phosphatase. CTC grade criteria: ALT Grade 1:\\>ULN 2.5\\*ULN; Grade 2: \\>2.5 - 5.0\\*ULN; Grade 3: \\>5.0 - 20.0\\*ULN; Grade 4: \\>20.0\\*ULN. AST Grade 1: \\>ULN - 2.5\\*ULN; Grade 2: \\>2.5 - 5.0\\*ULN; Grade 3: \\>5.0 - 20.0\\*ULN; Grade 4: \\>20.0\\*ULN. Total bilirubin Grade 1: \\>ULN - 1.5\\*ULN; Grade 2: \\>1.5 - 3.0\\*ULN; Grade 3: \\>3.0 - 10.0\\*ULN; Grade 4: \\>10.0\\*ULN. Albumin (low) Grade 1:\\<LLN - 3 grams per deciliter (g/dL)to \\<LLN - 3 g/dL; Grade 2: \\<3 - 2 g/dL to \\< 3.0 - 2.0 g/dL; Grade 3: \\< 2 g/dL to \\<2 g/L. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.","timeFrame":"Day 1 up to 30 days after last dose"},{"measure":"Number of Participants With Hematology Laboratory Abnormalities - Treated Population","description":"Hematology laboratories included hemoglobin, platelets, white blood cell (WBC) count, and absolute neutrophil count (ANC) and values were per CTC grading, 0, 1, 2, 3, 4. On-study laboratory tests were those performed after the start of study drug (from Day 2 of cycle 1) and up to 30 days after the last dose of study drug. WBC normal range: 4.1-12.3 x 10\\^3 /microliter (µL); platelets normal range: 140-450 x 10\\^9 /Liter (L); hemoglobin normal range 14-18 grams per deciliter (g/dL); ANC normal range: 2.03-8.36 x 10\\^9/μL.","timeFrame":"Day 2 up to 30 days after last dose"},{"measure":"Number of Participants With Renal Function Serum Chemistry Laboratory Abnormalities - Treated Population","description":"ULN=Upper limit of normal among all laboratory ranges; LLN=Lower limit of normal. CTC grade criteria: Sodium high (H) Grade (Gr) 1:\\>ULN - 150 millimoles per liter (mmol/L); Gr 2: \\>150 - 155 mmol/L; Gr 3: \\>155 - 160mmol/L; Gr 4: \\>160 mmol/L. Sodium low(L) Gr 1:\\<LLN - 130mmol/L; Gr 3: \\<130 - 120 mmol/L; Gr 4: \\<120 mmol/L. Potassium (H) Gr 1: \\>ULN - 5.5 mmol/L; Gr 2: \\>5.5 - 6.0 mmol/L; Gr 3: \\> 6.0 - 7.0 mmol/L; Gr 4: \\>7.0 mmol/L. Potassium (L) Gr 1: \\<LLN - 3.0 mmol/L; Gr 2: \\<LLN - 3.0 mmol/L; Gr 3: \\< 3.0 - 2.5 mmol/L; Gr 4: \\<2.5 mmol/L. Serum creatinine (H) Gr 1: \\>1 - 1.5\\*baseline (BL)to \\>ULN - 1.5\\*ULN; Gr 2: \\>1.5 - 3.0\\*BL to \\> 1.5 - 3.0\\*ULN; Gr 3: \\>3.0\\*BL to \\> 3.0 - 6.0\\*ULN; Gr 4: \\>6.0\\*ULN. Day 1 (start of study drug) to 30 days after last dose of any study drug, including monotherapy.","timeFrame":"Day 1 up to 30 days after last dose"},{"measure":"Number of Participants With Drug-Related Treatment-emergent AEs, Drug-Related SAEs, and Drug-Related AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population","description":"Drug-related AEs and drug-related SAEs (by investigator assessment) were those with a relationship to study drug(s) reported to Sponsor as related and those of unknown relationship. AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE was defined as a medical event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. MedDRA version 14.0. Severity of AEs were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Day 1 (start of study drug) to 30 days after last dose of any study drug, including monotherapy.","timeFrame":"Day 1 up to 30 days after last dose"},{"measure":"Number of Participants With Grades 3 and 4 Drug-Related Treatment-emergent AEs of Special Interest - Treated Population","description":"Drug-related AEs (investigator assessment): those with relationship to study drug(s)reported as related and those of unknown relationship. Special interest AEs: acneform rash, infusion reaction, cardiac adverse event, febrile neutropenia, infection (all terms except sepsis), sepsis, interstitial lung disease, renal failure, and thromboembolic events. Except for interstitial lung disease, these were composite terms combining several MedDRA terms (MedDRA version 14.0). Except for Gr 3 and 4 infusion reactions, AE severity per NCI-CTC, version 3.0: Gr 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Gr 3 - 4 infusion reactions: Gr 3=symptomatic bronchospasm, requiring parenteral medication(s), with or without urticaria; allergy-related edema/angioedema; Gr 4=life-threatening event with same Gr 3 symptomatology, complicated by symptomatic hypotension/oxygen saturation 70% or less. Day 1=start of study drug; to 30 days after last dose of any treatment.","timeFrame":"Day 1 up to 30 days after last dose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non-Small Cell Lung Cancer (NSCLC), Stage IV (per the American Joint Committee on Cancer (AJCC) Staging Manual, Seventh Edition) or recurrent disease following surgery and/or radiation therapy\n* Evaluable or measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n\nExclusion Criteria:\n\n* Uncontrolled Central Nervous System (CNS) metastasis.\n* Previous exposure to monoclonal antibodies, signal transduction inhibitors or Epidermal growth factor receptor (EGFR) targeting therapy\n* Concurrent malignancy\n* Prior chemotherapy for NSCLC\n* Pre-existing ascites grade ≥ 2 or pericardial effusion grade ≥ 2\n* Superior vena cava syndrome contra-indicating hydration\n* White Blood Cells (WBC) \\< 3,000/mm³\n* Absolute neutrophile count (ANC) \\< 1,500/mm³\n* Platelet \\< 100,000/mm³\n* Hemoglobin (Hgb) \\< 9.0 g/dL\n* Total bilirubin \\> 1.5 x Upper limit of normal (ULN).\n* Aspartate aminotransferase (AST) or Alanine-aminotransferase (ALT) \\> 5.0 x ULN.\n* Serum creatinine \\>1.25 x ULN and calculated creatinine clearance \\<60mL/min","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Donald W. Hill M.D., P.C.","city":"Casa Grande","state":"Arizona","zip":"85122","country":"United States","geoPoint":{"lat":32.8795,"lon":-111.75735}},{"facility":"Beverly Hills Cancer Center","city":"Beverly Hills","state":"California","zip":"90211","country":"United States","geoPoint":{"lat":34.07362,"lon":-118.40036}},{"facility":"Cancer Care Institute","city":"Los Angeles","state":"California","zip":"90036","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Northern California Hematology & Oncology","city":"Oakland","state":"California","zip":"94609","country":"United States","geoPoint":{"lat":37.80437,"lon":-122.2708}},{"facility":"Sharp Clinical Oncology Research","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Broward Oncology Associates, P.A.","city":"Fort Lauderdale","state":"Florida","zip":"33308","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"Elite Research Institute","city":"Miami","state":"Florida","zip":"33125","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Edward H. Kaplan, MD & Associates","city":"Skokie","state":"Illinois","zip":"60076","country":"United States","geoPoint":{"lat":42.03336,"lon":-87.73339}},{"facility":"Fairview Southdale Medical Oncology Clinic","city":"Edina","state":"Minnesota","zip":"55435","country":"United States","geoPoint":{"lat":44.88969,"lon":-93.34995}},{"facility":"Mid Dakota Clinic, Pc","city":"Bismarck","state":"North Dakota","zip":"58501","country":"United States","geoPoint":{"lat":46.80833,"lon":-100.78374}},{"facility":"Temple University Hospital","city":"Philadelphia","state":"Pennsylvania","zip":"19140","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"University Medical Center","city":"Lubbock","state":"Texas","zip":"79415","country":"United States","geoPoint":{"lat":33.57786,"lon":-101.85517}},{"facility":"Columbia Basin Hematology and Oncology","city":"Kennewick","state":"Washington","zip":"99336","country":"United States","geoPoint":{"lat":46.21125,"lon":-119.13723}},{"facility":"The Moncton Hospital","city":"Moncton","state":"New Brunswick","zip":"E1C 6Z8","country":"Canada","geoPoint":{"lat":46.09454,"lon":-64.7965}},{"facility":"Local Institution","city":"Grand Falls-Windsor","state":"Newfoundland and Labrador","zip":"A2A 2E2","country":"Canada","geoPoint":{"lat":48.93324,"lon":-55.66492}},{"facility":"Sudbury Regional Hospital","city":"Greater Sudbury","state":"Ontario","zip":"P3E 5J1","country":"Canada","geoPoint":{"lat":46.49,"lon":-80.99001}},{"facility":"The Credit Valley Hospital","city":"Mississauga","state":"Ontario","zip":"L5M 2N1","country":"Canada","geoPoint":{"lat":43.5789,"lon":-79.6583}},{"facility":"Thunder Bay Regional Health Sciences Centre (Regional Cancer Care)","city":"Thunder Bay","state":"Ontario","zip":"P7B 6V4","country":"Canada","geoPoint":{"lat":48.38202,"lon":-89.25018}},{"facility":"Toronto East General Hospital","city":"Toronto","state":"Ontario","zip":"M4C 3E7","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Centre de sante et de services sociaux de Rimouski-Neigette","city":"Rimouski","state":"Quebec","zip":"G5L 5T1","country":"Canada","geoPoint":{"lat":48.44879,"lon":-68.52396}},{"facility":"Ponce School of Medicine (Caimed Center)","city":"Ponce","zip":"00716","country":"Puerto Rico","geoPoint":{"lat":18.01031,"lon":-66.62398}},{"facility":"Fundacion de Investigacion de Diego","city":"San Juan","zip":"00927","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Investigator Inquiry form","url":"http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"72 participants were enrolled and 60 were treated with study drug. 12 not treated: 10 participants no longer met study criteria and 2 participants withdrew consent before entering the treatment phase.","recruitmentDetails":"First participant, first visit: 1 July 2010; Last participant, last visit: 7 September 2012. Participants were chemotherapy-naive with Stage IV histologically or cytologically documented non-small cell lung cancer (NSCLC). Participants treated until: progressive disease (PD)/ toxicity/patient-investigator decision.","groups":[{"id":"FG000","title":"Cetuximab + Cisplatin/Vinorelbine","description":"Intravenous (IV) cetuximab, 400mg per meter\\^2 (m\\^2), Week 1, then 250mg/m\\^2 weekly, until progressive disease (PD) or toxicity or participant-principal investigator (PPI)decision stopped treatment. One hour of observation required after each infusion. Cisplatin administered as IV solution at initial dose of 80mg/m\\^2 on the first day of each 21 day treatment cycle. Vinorelbine administered as IV solution at initial dose of 25 mg/m\\^2 on Day 1 and Day 8 of each 21 day treatment cycle. One cycle was defined as a 21-day treatment period, unless chemotherapy administration was delayed (cycle duration was longer). All study drugs discontinued if participants experienced PD. If unacceptable toxicities to any study drug occurred, any drug could be modified (reduced, delayed, omitted, or discontinued) independently of the other drugs If no PD, cetuximab could be given as monotherapy after completion of the 6 treatment cycles or after early discontinuation of cis/vin due to intolerance."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"60"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"57"}]}],"dropWithdraws":[{"type":"Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"29"}]},{"type":"Study Drug toxicity","reasons":[{"groupId":"FG000","numSubjects":"6"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Maximum clinical benefit","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"No longer meets criteria","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Participant requested to end treatment","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All treated participants.","groups":[{"id":"BG000","title":"Cetuximab + Cisplatin/Vinorelbine","description":"Intravenous (IV) cetuximab, 400mg per meter\\^2 (m\\^2), Week 1, then 250mg/m\\^2 weekly, until progressive disease (PD) or toxicity or participant-principal investigator (PPI) decision stopped treatment. One hour of observation required after each infusion. Cisplatin administered as IV solution at initial dose of 80mg/m\\^2 on the first day of each 21 day treatment cycle. Vinorelbine administered as IV solution at initial dose of 25 mg/m\\^2 on Day 1 and Day 8 of each 21 day treatment cycle. One cycle was defined as a 21-day treatment period, unless chemotherapy administration was delayed (cycle duration was longer). All study drugs discontinued if participants experienced PD. If unacceptable toxicities to any study drug occurred, any drug could be modified (reduced, delayed, omitted, or discontinued) independently of the other drugs If no PD, cetuximab could be given as monotherapy after completion of the 6 treatment cycles or after early discontinuation of cis/vin due to intolerance."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"60"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"36"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"24"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.8","spread":"10.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"23"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"37"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}]},{"title":"Puerto Rico","categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}]},{"title":"Canada","categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}]}]},{"title":"ECOG PS at baseline","description":"ECOG PS = Eastern Cooperative Oncology Group Performance Status. Baseline is defined as values obtained during the screening period, prior to treatment with study drug. Inclusion criteria included those participants with values of 0, 1 or 2. ECOG=performance questionnaire with a scale of 6 units (0 to 5) with the higher numbers reflecting a worse outcome: 0=fully active, carry on performance without restriction; 1=restricted in physically strenuous activity but ambulatory, 2= ambulatory and capable of self care; 3=capable of limited self care, confined to bed; 4=completely disabled; 5=dead.","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"0","categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}]},{"title":"1","categories":[{"measurements":[{"groupId":"BG000","value":"38"}]}]},{"title":"2","categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Any Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population","description":"AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=medical event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. MedDRA version 14.0. Severity of AEs were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.","populationDescription":"Treated population: all participants who received at least one dose of any study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 up to 30 days after last dose","groups":[{"id":"OG000","title":"Cetuximab + Cisplatin/Vinorelbine","description":"Intravenous (IV) cetuximab, 400mg per meter\\^2 (m\\^2), Week 1, then 250mg/m\\^2 weekly, until progressive disease (PD) or toxicity or participant-principal investigator (PPI) decision stopped treatment. One hour of observation required after each infusion. Cisplatin administered as IV solution at initial dose of 80mg/m\\^2 on the first day of each 21 day treatment cycle. Vinorelbine administered as IV solution at initial dose of 25 mg/m\\^2 on Day 1 and Day 8 of each 21 day treatment cycle. One cycle was defined as a 21-day treatment period, unless chemotherapy administration was delayed (cycle duration was longer). All study drugs discontinued if participants experienced PD. If unacceptable toxicities to any study drug occurred, any drug could be modified (reduced, delayed, omitted, or discontinued) independently of the other drugs If no PD, cetuximab could be given as monotherapy after completion of the 6 treatment cycles or after early discontinuation of cis/vin due to intolerance."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"classes":[{"title":"Deaths due to disease progression","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Deaths due to Other Causes","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"SAE (any grade)","categories":[{"measurements":[{"groupId":"OG000","value":"38"}]}]},{"title":"AE (any grade)","categories":[{"measurements":[{"groupId":"OG000","value":"59"}]}]},{"title":"AE Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"46"}]}]},{"title":"AE that led to Discontinuation of study drug","categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Grades 3 and 4 Treatment-emergent Adverse Events (AEs) of Special Interest - Treated Population","description":"Special interest AEs: acneform rash, infusion reaction, cardiac adverse event, febrile neutropenia, infection (includes all terms except sepsis), sepsis, interstitial lung disease, renal failure, and thromboembolic events. Except for interstitial lung disease, these were composite terms combining several preferred/other level MedDRA terms (MedDRA version 14.0). Except for Grade (GR)3 and 4 infusion reactions, AE severity were graded per the NCI-CTC, version 3.0: Gr 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Severity of Gr 3 - 4 infusion reactions were: Gr 3=symptomatic bronchospasm, requiring parenteral medication(s), with or without urticaria; allergy-related edema/angioedema; Gr 4=a life-threatening event characterized by the same symptomatology as a Gr 3, complicated by symptomatic hypotension or oxygen saturation 70% or less. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.","populationDescription":"Treated population: all participants who received at least one dose of any study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 to 30 days after last dose","groups":[{"id":"OG000","title":"Cetuximab + Cisplatin/Vinorelbine","description":"Intravenous (IV) cetuximab, 400mg per meter\\^2 (m\\^2), Week 1, then 250mg/m\\^2 weekly, until progressive disease (PD) or toxicity or participant-principal investigator (PPI) decision stopped treatment. One hour of observation required after each infusion. Cisplatin administered as IV solution at initial dose of 80mg/m\\^2 on the first day of each 21 day treatment cycle. Vinorelbine administered as IV solution at initial dose of 25 mg/m\\^2 on Day 1 and Day 8 of each 21 day treatment cycle. One cycle was defined as a 21-day treatment period, unless chemotherapy administration was delayed (cycle duration was longer). All study drugs discontinued if participants experienced PD. If unacceptable toxicities to any study drug occurred, any drug could be modified (reduced, delayed, omitted, or discontinued) independently of the other drugs If no PD, cetuximab could be given as monotherapy after completion of the 6 treatment cycles or after early discontinuation of cis/vin due to intolerance."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"classes":[{"title":"Grade 3-4 acneform rash","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Grade 3-4 infusion reaction","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Cardiac events Grade 3-4","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Infection Grade 3-4","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Sepsis Grade 3-4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Renal failure Grade 3-4","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Thromboembolic events Grade 3-4","categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]},{"title":"Interstitial lung disease Grade 3-4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Febrile neutropenia Grade 3-4","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Liver Function Serum Chemistry Laboratory Abnormalities - Treated Population","description":"ULN=Upper limit of normal among all laboratory ranges. ALT=alanine transaminase; AST=aspartate aminotransferase; ALP=alkaline phosphatase. CTC grade criteria: ALT Grade 1:\\>ULN 2.5\\*ULN; Grade 2: \\>2.5 - 5.0\\*ULN; Grade 3: \\>5.0 - 20.0\\*ULN; Grade 4: \\>20.0\\*ULN. AST Grade 1: \\>ULN - 2.5\\*ULN; Grade 2: \\>2.5 - 5.0\\*ULN; Grade 3: \\>5.0 - 20.0\\*ULN; Grade 4: \\>20.0\\*ULN. Total bilirubin Grade 1: \\>ULN - 1.5\\*ULN; Grade 2: \\>1.5 - 3.0\\*ULN; Grade 3: \\>3.0 - 10.0\\*ULN; Grade 4: \\>10.0\\*ULN. Albumin (low) Grade 1:\\<LLN - 3 grams per deciliter (g/dL)to \\<LLN - 3 g/dL; Grade 2: \\<3 - 2 g/dL to \\< 3.0 - 2.0 g/dL; Grade 3: \\< 2 g/dL to \\<2 g/L. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.","populationDescription":"Number (N) of participants with laboratory data available and who could be analyzed for total bilirubin was 49. All other liver function laboratories N=57. Treated population: all participants who received at least one dose of any study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 up to 30 days after last dose","groups":[{"id":"OG000","title":"Cetuximab + Cisplatin/Vinorelbine","description":"Intravenous (IV) cetuximab, 400mg per meter\\^2 (m\\^2), Week 1, then 250mg/m\\^2 weekly, until progressive disease (PD) or toxicity or participant-principal investigator (PPI) decision stopped treatment. One hour of observation required after each infusion. Cisplatin administered as IV solution at initial dose of 80mg/m\\^2 on the first day of each 21 day treatment cycle. Vinorelbine administered as IV solution at initial dose of 25 mg/m\\^2 on Day 1 and Day 8 of each 21 day treatment cycle. One cycle was defined as a 21-day treatment period, unless chemotherapy administration was delayed (cycle duration was longer). All study drugs discontinued if participants experienced PD. If unacceptable toxicities to any study drug occurred, any drug could be modified (reduced, delayed, omitted, or discontinued) independently of the other drugs If no PD, cetuximab could be given as monotherapy after completion of the 6 treatment cycles or after early discontinuation of cis/vin due to intolerance."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"}]}],"classes":[{"title":"Albumin (low) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"37"}]}]},{"title":"Albumin (low) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Total bilirubin (high) Grade 1 - 4 (N=49)","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Total bilirubin (high) Grade 3 or 4 (N=49)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"ALT (high) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}]},{"title":"ALT (high) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"ALP (high) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}]},{"title":"ALP (high) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"AST (high) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]},{"title":"AST (high) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Hematology Laboratory Abnormalities - Treated Population","description":"Hematology laboratories included hemoglobin, platelets, white blood cell (WBC) count, and absolute neutrophil count (ANC) and values were per CTC grading, 0, 1, 2, 3, 4. On-study laboratory tests were those performed after the start of study drug (from Day 2 of cycle 1) and up to 30 days after the last dose of study drug. WBC normal range: 4.1-12.3 x 10\\^3 /microliter (µL); platelets normal range: 140-450 x 10\\^9 /Liter (L); hemoglobin normal range 14-18 grams per deciliter (g/dL); ANC normal range: 2.03-8.36 x 10\\^9/μL.","populationDescription":"Treated population: all participants who received at least one dose of any study drug. Participants with at least one on-study laboratory measurement available were analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 2 up to 30 days after last dose","groups":[{"id":"OG000","title":"Cetuximab + Cisplatin/Vinorelbine","description":"Intravenous (IV) cetuximab, 400mg per meter\\^2 (m\\^2), Week 1, then 250mg/m\\^2 weekly, until progressive disease (PD) or toxicity or participant-principal investigator (PPI) decision stopped treatment. One hour of observation required after each infusion. Cisplatin administered as IV solution at initial dose of 80mg/m\\^2 on the first day of each 21 day treatment cycle. Vinorelbine administered as IV solution at initial dose of 25 mg/m\\^2 on Day 1 and Day 8 of each 21 day treatment cycle. One cycle was defined as a 21-day treatment period, unless chemotherapy administration was delayed (cycle duration was longer). All study drugs discontinued if participants experienced PD. If unacceptable toxicities to any study drug occurred, any drug could be modified (reduced, delayed, omitted, or discontinued) independently of the other drugs If no PD, cetuximab could be given as monotherapy after completion of the 6 treatment cycles or after early discontinuation of cis/vin due to intolerance."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"}]}],"classes":[{"title":"Hemoglobin (low) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"51"}]}]},{"title":"Hemoglobin (low) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Hemoglobin (low) Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Platelets (low) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]},{"title":"Platelets (low) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Platelets (low) Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"WBC (low) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}]},{"title":"WBC (low) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}]},{"title":"WBC (low) Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"ANC (low) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"47"}]}]},{"title":"ANC (low) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"38"}]}]},{"title":"ANC (low) Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Renal Function Serum Chemistry Laboratory Abnormalities - Treated Population","description":"ULN=Upper limit of normal among all laboratory ranges; LLN=Lower limit of normal. CTC grade criteria: Sodium high (H) Grade (Gr) 1:\\>ULN - 150 millimoles per liter (mmol/L); Gr 2: \\>150 - 155 mmol/L; Gr 3: \\>155 - 160mmol/L; Gr 4: \\>160 mmol/L. Sodium low(L) Gr 1:\\<LLN - 130mmol/L; Gr 3: \\<130 - 120 mmol/L; Gr 4: \\<120 mmol/L. Potassium (H) Gr 1: \\>ULN - 5.5 mmol/L; Gr 2: \\>5.5 - 6.0 mmol/L; Gr 3: \\> 6.0 - 7.0 mmol/L; Gr 4: \\>7.0 mmol/L. Potassium (L) Gr 1: \\<LLN - 3.0 mmol/L; Gr 2: \\<LLN - 3.0 mmol/L; Gr 3: \\< 3.0 - 2.5 mmol/L; Gr 4: \\<2.5 mmol/L. Serum creatinine (H) Gr 1: \\>1 - 1.5\\*baseline (BL)to \\>ULN - 1.5\\*ULN; Gr 2: \\>1.5 - 3.0\\*BL to \\> 1.5 - 3.0\\*ULN; Gr 3: \\>3.0\\*BL to \\> 3.0 - 6.0\\*ULN; Gr 4: \\>6.0\\*ULN. Day 1 (start of study drug) to 30 days after last dose of any study drug, including monotherapy.","populationDescription":"Treated population: All participants who received at least one dose of any study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 up to 30 days after last dose","groups":[{"id":"OG000","title":"Cetuximab + Cisplatin/Vinorelbine","description":"Intravenous (IV) cetuximab, 400mg per meter\\^2 (m\\^2), Week 1, then 250mg/m\\^2 weekly, until progressive disease (PD) or toxicity or participant-principal investigator (PPI) decision stopped treatment. One hour of observation required after each infusion. Cisplatin administered as IV solution at initial dose of 80mg/m\\^2 on the first day of each 21 day treatment cycle. Vinorelbine administered as IV solution at initial dose of 25 mg/m\\^2 on Day 1 and Day 8 of each 21 day treatment cycle. One cycle was defined as a 21-day treatment period, unless chemotherapy administration was delayed (cycle duration was longer). All study drugs discontinued if participants experienced PD. If unacceptable toxicities to any study drug occurred, any drug could be modified (reduced, delayed, omitted, or discontinued) independently of the other drugs If no PD, cetuximab could be given as monotherapy after completion of the 6 treatment cycles or after early discontinuation of cis/vin due to intolerance."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"}]}],"classes":[{"title":"Sodium (low) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"42"}]}]},{"title":"Sodium (low) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}]},{"title":"Sodium (low) Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Sodium (high) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Sodium (high) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Sodium (high) Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Potassium (low) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}]},{"title":"Potassium (low) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]},{"title":"Potassium (low) Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Potassium (high) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Potassium (high) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Potassium (high) Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Serum Creatinine (high) Grade 1 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]},{"title":"Serum Creatinine (high) Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Serum Creatinine (high) Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Drug-Related Treatment-emergent AEs, Drug-Related SAEs, and Drug-Related AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population","description":"Drug-related AEs and drug-related SAEs (by investigator assessment) were those with a relationship to study drug(s) reported to Sponsor as related and those of unknown relationship. AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE was defined as a medical event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. MedDRA version 14.0. Severity of AEs were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Day 1 (start of study drug) to 30 days after last dose of any study drug, including monotherapy.","populationDescription":"Treated population: All participants who received at least one dose of any study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 up to 30 days after last dose","groups":[{"id":"OG000","title":"Cetuximab + Cisplatin/Vinorelbine","description":"Intravenous (IV) cetuximab, 400mg per meter\\^2 (m\\^2), Week 1, then 250mg/m\\^2 weekly, until progressive disease (PD) or toxicity or participant-principal investigator (PPI) decision stopped treatment. One hour of observation required after each infusion. Cisplatin administered as IV solution at initial dose of 80mg/m\\^2 on the first day of each 21 day treatment cycle. Vinorelbine administered as IV solution at initial dose of 25 mg/m\\^2 on Day 1 and Day 8 of each 21 day treatment cycle. One cycle was defined as a 21-day treatment period, unless chemotherapy administration was delayed (cycle duration was longer). All study drugs discontinued if participants experienced PD. If unacceptable toxicities to any study drug occurred, any drug could be modified (reduced, delayed, omitted, or discontinued) independently of the other drugs If no PD, cetuximab could be given as monotherapy after completion of the 6 treatment cycles or after early discontinuation of cis/vin due to intolerance."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"classes":[{"title":"Drug-related SAE (any grade)","categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]},{"title":"Drug-related AE (any grade)","categories":[{"measurements":[{"groupId":"OG000","value":"54"}]}]},{"title":"Drug-related AE Grade 3 or 4","categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}]},{"title":"Drug-related AE led to Discontinuation of drug","categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Grades 3 and 4 Drug-Related Treatment-emergent AEs of Special Interest - Treated Population","description":"Drug-related AEs (investigator assessment): those with relationship to study drug(s)reported as related and those of unknown relationship. Special interest AEs: acneform rash, infusion reaction, cardiac adverse event, febrile neutropenia, infection (all terms except sepsis), sepsis, interstitial lung disease, renal failure, and thromboembolic events. Except for interstitial lung disease, these were composite terms combining several MedDRA terms (MedDRA version 14.0). Except for Gr 3 and 4 infusion reactions, AE severity per NCI-CTC, version 3.0: Gr 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Gr 3 - 4 infusion reactions: Gr 3=symptomatic bronchospasm, requiring parenteral medication(s), with or without urticaria; allergy-related edema/angioedema; Gr 4=life-threatening event with same Gr 3 symptomatology, complicated by symptomatic hypotension/oxygen saturation 70% or less. Day 1=start of study drug; to 30 days after last dose of any treatment.","populationDescription":"Treated population: All participants who received at least one dose of any study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 up to 30 days after last dose","groups":[{"id":"OG000","title":"Cetuximab + Cisplatin/Vinorelbine","description":"Intravenous (IV) cetuximab, 400mg per meter\\^2 (m\\^2), Week 1, then 250mg/m\\^2 weekly, until progressive disease (PD) or toxicity or participant-principal investigator (PPI) decision stopped treatment. One hour of observation required after each infusion. Cisplatin administered as IV solution at initial dose of 80mg/m\\^2 on the first day of each 21 day treatment cycle. Vinorelbine administered as IV solution at initial dose of 25 mg/m\\^2 on Day 1 and Day 8 of each 21 day treatment cycle. One cycle was defined as a 21-day treatment period, unless chemotherapy administration was delayed (cycle duration was longer). All study drugs discontinued if participants experienced PD. If unacceptable toxicities to any study drug occurred, any drug could be modified (reduced, delayed, omitted, or discontinued) independently of the other drugs If no PD, cetuximab could be given as monotherapy after completion of the 6 treatment cycles or after early discontinuation of cis/vin due to intolerance."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"classes":[{"title":"drug-related acneform rash Grade 3 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"drug-related infusion reaction Grade 3 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"drug-related cardiac events Grade 3 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"drug-related infection Grade 3 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"drug-related sepsis Grade 3 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"drug-related interstitial lung disease Grade 3 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"drug-related renal failure Grade 3 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"drug-related thromboembolic events Grade 3 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"drug-related febrile neutropenia Grade 3 - 4","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Day 1 up to 30 days after last dose of study drug. Participants were in the study until disease progression or toxicity/decision by patient-investigator.","eventGroups":[{"id":"EG000","title":"Cetuximab + Cisplatin/Vinorelbine","description":"Intravenous (IV) cetuximab, 400mg per meter squared (m²), week 1, then 250mg/m² weekly, until progressive disease (PD) or toxicity or participant-principal investigator (PPI)decision stopped the treatment. One hour of observation required after each infusion. IV cisplatin, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles. Pre-cisplatin hydration could begin during 1-hour post cetuximab observation period. IV vinorelbine, 80mg/m², Day 1 of each 21 day cycle, maximum 6 cycles. One cycle was defined as a 21-day treatment period, unless chemotherapy administration was delayed (cycle duration was longer). All study drugs discontinued if participants experienced PD. If unacceptable toxicities to any study drug occurred, any drug could be modified (reduced, delayed, omitted, or discontinued) independently of the other drugs If no PD, cetuximab could be given as monotherapy after completion of the 6 treatment cycles or after early discontinuation of cis/vin due to intolerance.","seriousNumAffected":38,"seriousNumAtRisk":60,"otherNumAffected":59,"otherNumAtRisk":60}],"seriousEvents":[{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Metastases to spine","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Administration site abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Diverticular perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":60}]},{"term":"Neutropenic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":60}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":60}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":60}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":60}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Lung neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":60}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":60}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Lung infection pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":60}]}],"otherEvents":[{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":60}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":34,"numAtRisk":60}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":60}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":60}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":60}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":60}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":60}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":60}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":60}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":60}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":60}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":60}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":60}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":60}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":60}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":60}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":60}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":60}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":60}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":60}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":60}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":60}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":60}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":60}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":60}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":60}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":60}]},{"term":"Hypertrichosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":60}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":60}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":60}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":60}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":60}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":60}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":60}]},{"term":"Nail infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Neutrophil count","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":60}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":60}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":60}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":60}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":60}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":60}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":60}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":60}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":60}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":60}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":60}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":60}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":60}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":60}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":60}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":60}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":60}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":60}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":60}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":60}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":60}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":60}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":60}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D008175","term":"Lung Neoplasms"},{"id":"D002277","term":"Carcinoma"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068818","term":"Cetuximab"},{"id":"D002945","term":"Cisplatin"},{"id":"D000077235","term":"Vinorelbine"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D014748","term":"Vinca Alkaloids"},{"id":"D046948","term":"Secologanin Tryptamine Alkaloids"},{"id":"D026121","term":"Indole Alkaloids"},{"id":"D000470","term":"Alkaloids"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D007211","term":"Indoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D054836","term":"Indolizidines"},{"id":"D007212","term":"Indolizines"}]}},"hasResults":true}